Jul 12 2010
Penn Pharma and Xcelience, LLC today announced that the two companies have entered into a joint venture agreement to provide Capsugel's Xcelodose® precision powder micro-dosing system technology on a global basis.
“This joint venture will create a powerful partnership between two leading providers who share a common commitment to quality, innovation, and building client relationships based on trust and performance”
The joint venture provides pharmaceutical and biotechnology companies the opportunity to manufacture first in human batches faster and closer to the clinical sites. The companies will operate the largest network of Xcelodose® systems worldwide guaranteeing immediate manufacturing capacity.
"This joint venture will create a powerful partnership between two leading providers who share a common commitment to quality, innovation, and building client relationships based on trust and performance," said Derek Hennecke, CEO & President of Xcelience. "Xcelience has more than six years experience in powder in capsule technology and has processed more than 100 clinical supply batches using the Xcelodose technology," notes Paul Wituschek, Global Sales & Marketing Director of Penn. "Penn will be able to immediately leverage this expertise to provide this important accelerated development option to our clients."
SOURCE Penn Pharma and Xcelience